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Abstract
Background: Human bocavirus (HBoV) is a recently discovered parvovirus associated with mild to severe lower
respiratory tract infections in children, the aim of the work was determination of human bocavirus in
nasopharyngeal aspirate (NPA) of infants by qualitative PCR and determination of acute human bocavirus infection
by estimation of immunoglobulin M (IgM) antibodies in serum by enzyme linked immunosorbent assay.
Results: Twenty two (22%) out of the 100 NPA specimens of the patients with respiratory manifestations were
positive for HBoV by qualitative PCR, while ELISA revealed positive HBoV IgM antibodies in 18 (18%) patients who
were also positive by PCR. Non of the controls were positive by both techniques. The correlation study between
ELISA and PCR revealed high significant association, (p < 0.001, X
2 = 36 and agreement = 96%). Also PCR detected
4 (18.1%) NPA samples as HBoV positive cases among the patients that were not identified by ELISA. This could be
due to high sensitivity and efficacy of PCR. ELISA being less sensitive than RT-PCR, sensitivity was (81.8% vs 100%),
the efficacy was 97.7% in ELISA versus 99.7% for RT-PCR.
Conclusion: HBoV infections could be diagnosed in NPA of children by conventional PCR as a rapid and sensitive
technique. While ELISA was a reliable serologic analysis for diagnosis of acute HBoV infection by estimation IgM
antibodies in serum.
Background
In 2005, Allander et al., [1] reported the discovery of a pre-
viously undescribed human parvovirus in respiratory secre-
tions from children with respiratory tract disease in
Sweden. Phylogenetic analysis showed that this virus
belonged to the genus Bocavirus (subfamily, Parvovirinae;
family, Parvoviridae) and was most closely related to bovine
parvovirus (BP) and minute virus of canines (MVC). The
virus was thus named “human bocavirus” (HBoV).
Human bocaviruses (HBoV) contain 3 open reading
frames (ORFs) encoding a nonstructural protein (NS1,
NP1) and two capsid proteins VP1 and VP2, respectively
[2]. The genomic organization of HBoV closely resembles
that of bovine parvovirus type 1 [1].
HBoV has been reported in respiratory samples from
children with acute respiratory tract disease in various
parts of the world (including Australia, North America,
Europe, Asia, and Africa), suggesting that the virus is
circulating worldwide [3]. Pneumonia, acute bronchitis,
bronchiolitis, are the main manifestations of HBoV
infection [4].
HBoV seems to be a new member of the community-
acquired respiratory viruses such as respiratory syncytial
virus, adenovirus, influenza virus, parainfluenza virus, and
rhinovirus, which cause common respiratory tract infec-
tions in the community [5]. Because of its very high copy
numbers in respiratory tract secretions, aerosol and con-
tact transmission are likely effective, as they are for other
respiratory viruses [6].
HBoV has been detected also in nasopharyngeal,
serum, fecal and urine samples obtained mainly from
young children around the age of 2 years predominantly
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pediatric patients after organ transplantation [7], in
human immunodeficiency virus-infected pediatric
patients [8], and immunosuppressed adult patients [9].
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amplification of viral genome fragments present in
human respiratory, serum, stool and urine samples. A
great number of different PCR techniques employing
varying sets of primers specific for the viral genes NP1
[10], NS1 [11], and VP1, VP2 [12,13] have been
described. In addition to the detection of viral genomes
by PCR, recent reports describe the detection of HBoV-
specific IgG and IgM-antibodies against HBoV VP2 in
serum samples using western blot [14] or immunofluor-
escence assays [2,15]. Furthermore, a standardized
ELISA for the quantitative determination of HBoV-spe-
cific antibodies has been established by [16]. The aim of
the work was determination of HBoV in respiratory spe-
cimens (NPA) of infants by qualitative PCR and deter-
mination of acute HBoV infection by estimation of IgM
antibodies in serum by ELISA.
Results
Microbiological results
Cultures of nasopharyngeal aspirates from 100 patients
were positive in 67% of patients. Cultures yielded
growth of one or more pathogen among upper respira-
tory tract normal flora. Gram positive cocci were iso-
lated from 57/90 (63.3%) of specimens including:
Streptococcus pneumoniae 25/90 (27.7%), Staphylococcus
aureus 32/90 (35.5%). Gram negative bacilli were
detected in 33/90(36.6%) of specimens including, Kleb-
siella pneumoniae 15/90 (16.6%), Escherichia coli 10/90
(11.1%), Pseudomonas aeruginosa 8/90 (8.8%), while
Cultures of the control group showed growth of upper
respiratory tract normal flora (table 1).
Qualitative PCR results
Twenty two (22%) out of the 100 NPA specimens of the
patients were positive for HBoV and 78 (78%) specimens
were negative by qualitative PCR. While all the 50 NPA
of the control group were negative for HBoV. Also there
was a high significant difference between the patient and
the control groups since p < 0.001 (table 2).
ELISA results
Eighteen (18%) out of the 100 serum samples of the
patients with respiratory tract manifestations were posi-
tive for HBoV IgM antibodies by ELISA such patients
are also positive by PCR, and 82 (82%) specimens were
HBoV negative by ELISA. While all 50 serum samples
of the controls were negative (table 3). Serum concen-
tration of IgM antibodies against HBoV were detected
significantly in patients (0.28 ± 0.06 vs 0.07 ± 0.01 con-
trols), p < 0.001. Table 4 showed the number of positive
cases by the different diagnostic methods. Table 5
showed that there was a highly significant association
between the PCR and ELISA techniques.
Diagnostic validity tests
Diagnostic validity test including sensitivity, specificity,
predictive values and efficacy of both HBoV ELISA and
PCR were calculated (table 6 and 7) considering PCR as
a reference method. In our work we found ELISA to be
less sensitive than PCR, it was (81.8% vs 100%), but the
specificity of ELISA is higher than PCR, it was (100% vs
78%) (table 6 and 7).
Discussion
In recent years, several novel viruses have been discov-
ered in patients with respiratory infections using mole-
cular biology methods. These novel viruses include the
human metapneumovirus and several coronaviruses
(SARS, NL63, and HKU1) [17,18] the latest addition to
this list was the human bocavirus (HBoV).
Attempts to culture this virus on conventional cell
lines had failed but, Dijkman et al., [19] had investigated
whether the virus can replicate on pseudostratified
human airway epithelium. The cells were inoculated
with human bocavirus-positive nasopharyngeal washes
from children, and virus replication was monitored by
measuring apical release of the virus via real-time PCR.
Electron Microscopy supported the ultrastructure ana-
lysis of the HBoV virus like particles (VLP) using a
Table 1 The isolated bacteria in NPA specimens of patients with respiratory tract infection
Organism Number (%) Organism spp. IsolateNumber (%)
Gram positive cocci Streptococcus pneumoniae 25/90 (27.7%)
57/90(63.3%) Staphylococcus aureus 32/90 (35.5%)
Gram negative bacilli Klebsiella pneumoniae 15/90 (16.6%)
33/90(36.6%) E. coli 10/90 (11.1%)
Pseudomonas aeruginosa 8/90 (8.8%)
Normal flora 33 (33%)
Total 100 (100%)
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camera [20].
In our work 22 (22%) out of the 100 NPA specimens of
the patients were positive for HBoV, There was a high
significant difference between the patient and the control
groups (p < 0.001). PCR detected four HBoV positive
cases that were negative by ELISA, this could be
explained by the high sensitivity of PCR over ELISA since
it was (100% vs 81.1%) respectively. Weissbrich et al., [21]
had found HBoV DNA in (10.3%) of NPA samples
obtained from 786 hospitalized infants and children with
febrile respiratory tract diseases during the years 2002 to
2005 in the region of northern Bavaria in Germany.
While Neske et al., [22] had studied 834 nasopharyngeal
aspirates (NPA), 10 serum samples, and 31 stool samples
of children with acute respiratory diseases. For phyloge-
netic analysis, the VP2 genes were sequenced from 69
HBoV-positive NPA samples. The qualitative results of
the real-time HBoV PCR were in good agreement with a
conventional HBoV PCR. They found that 12% of the
NPA were positive for HBoV DNA by both techniques.
Söderlund-Venermo et al., [23] reported that the unique
region in VP1 is less immunogenic than the major virus
capsid protein VP2, Also he expressed HBoV VP2 viral
like particles (VLPs) in insect cells for use in IgM and IgG
ELISA that are superior to immunoblots in diagnostic
performance.
In the present study 18 (18%) out of the 100 serum sam-
ples of the patients with respiratory tract manifestations
were positive for HBoV IgM antibodies by ELISA. There
was a significant difference between the patient and the
control group (p < 0.001). The mean serum concentration
of IgM antibodies against HBoV, in the two groups was
(0.28 ± 0.06 vs 0.07 ± 0.01). There was also a highly signifi-
cant association between PCR and ELISA techniques (p <
0.001 and agreement = 96%). Söderlund-Venermo et al.,
[23] diagnosed acute primary HBoV infections in 49 (19%)
of 258 children with expiratory wheezing, and Lindner et
al., [24] detected IgM against HBoV by ELISA in 10/24
(42%) of sera samples obtained from HBoV DNA-positive
children and infants with infections of the respiratory
tract.
In the present study sensitivity, specificity, positive
predictive value and efficacy of ELISA were
81.8%,100%,100% and 97.7% respectively Lindner et al.,
[16] had reported diagnostic sensitivity and specificity of
their antibody ELISA were as high as 97% and 99.5%,
respectively; positive predictive value was 97% by using
ELISA among wheezing children.
Conclusion
HBoV infections could be diagnosed in NPA by conven-
tional PCR as a rapid and sensitive technique. ELISA
was a reliable serologic analysis for diagnosis of acute
HBoV infection by estimation IgM antibodies in serum.
Methods
The present case - control study was conducted on 100
patients aged from 1 to 5 years (61 males and 39
females) with a mean ± SD age of (2.7 ± 1.1) attending
the Pediatric outpatient clinic, Ain Shams University
Hospitals, Cairo, Egypt in the period from September
2009 to May 2010. Patients were suffering from lower
respiratory tract infection together with upper respira-
tory tract manifestations such as cough, running nose
and fever. In addition to 50 apparently healthy children
(32 males and 18 females) matched in age with the
patients as a control group.
All patients were subjected to the following after their
written consent, full history taking and thorough clinical
examination, complete blood picture, chest plain X-ray.
Nasopharyngeal aspirate (NPA) samples collected from
Table 3 Comparison between patients and controls by
ELISA







P < 0.001 (highly significant).
Table 4 Number of positive cases by the different
diagnostic methods
Method No. of HBoV (+) cases No. of HBoV (-) cases Total
N (%) N (%)
PCR 22 22 78 78 100
ELISA 18 18 82 82 100
Table 5 Correlation between PCR and ELISA
ELISA (-) ELISA (+) Total
PCR (-) Number 78 0 78
%/total 95.1 0 78
PCR (+) Number 41 82 2
%/total 4.9 100 22
Total 82 18 100
X
2 = 36, P < 0.001, Agreement = 96%.
Table 2 Comparison between patients and controls by
PCR







P < 0.001 (highly significant).
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microbiological examination and qualitative polymerase
chain reaction (PCR) for detection HBoV. Serum sam-
ples were collected from both patient and control
groups for detection of HBoV- IgM antibodies by
ELISA.
Sample collection
Nasopharyngeal aspirates were collected from patients
and control group according to Svensson et al., [25]. Ster-
ile normal saline solution was instilled in one nostril
while occluding the other nostril, using a sterile blunt-
tipped disposable syringe. Then the patient was
instructed to forcibly exhale through the lavaged side
into a sterile specimen cup. The sequence was then
repeated in the other side of the nose. NPA specimens
were examined microbiologically immediately and part of
the specimens was stored in aliquots at -70°C for PCR.
Two ml blood samples from both patients and control
were collected into vacutainer, centrifuged and serum
was separated and stored at - 20°C for HBoV-IgM anti-
bodies by ELISA.
Microbiological examination
It was done by Gram stained smear for detection of pus
cells and microorganisms. Quantitative culture of NPA
specimens of patients and control was done. Undiluted
and tenfold serial dilutions were inoculated with a cali-
brated loop on chocolate agar, blood agar and MacCon-
k e ya g a rp l a t e s ,a f t e ro v e rn i g h ti n c u b a t i o ni n
appropriate conditions, Quantitative NPA cultures were
considered positive when the growth of 10
6 (cfu/ml) or
more was observed [26].
Qualitative polymerase chain reaction (PCR)
DNA was extracted from 200 μl of the NPA samples
using the High Pure Viral Nucleic Acid Kit (Roche,
Mannheim, Germany) according to the instructions of
the manufacturer.
Amplification of hBoV DNA was performed using 50
μl elution volume with the NP-1 primers BoV188F and
BoV542R described by Allander et al., [1] (table 8) using
the HotStarTaq DNA Polymerase (Qiagen, Hilden, Ger-
many). PCR reactions were carried out in a 50 μl
volume consisting of 5 μl extracted DNA, 1× Qiagen
HotStar buffer, dNTPs at a final concentration of 200
μM each, 200 pmol of each primer, and 1.5 U of Taq
Polymerase. The cycling conditions were 50 cycles (94°C
30 s, 53°C 40 s and 1 min at 72°C) after a preheating
step of 10 min at 95°C.
After amplification, PCR products were visualized by
staining with ethidium bromide on agarose gels. A PCR
reaction was considered as positive when a band of the
expected size (354 base pairs) was visible.
A plasmid containing the PCR product cloned in the
vector PCR 2.1-TOPO (Invitrogen) was used as positive
control.
Enzyme linked immunosorbent assay (ELISA)
HBoV-IgM antibodies were determined by a commercially
available immunoglobulin M (IgM) enzyme-linked immu-
nosorbent assay supplied by (Dako, Glostrup, Denmark)
for the quantitative determination of IgM antibodies to
HBoV in serum. Briefly: serum samples diluted 1:200 in
phosphate buffer saline (PBS) and 0.05% Tween (PBST)
were applied in duplicate into wells of plates coated with
goat anti-human IgM for 60 min at room temperature.
After being rinsed 5 times with PBST, biotinylated HBoV
viral like particles (VLPs) were applied at a concentration
of 25 ng/well and incubated for 45 min at 37°C. Bound
antigen was visualized by using horseradish peroxidase-
conjugated streptavidin at 1:12,000 in PBST plus 0.5%
bovine serum albumin for 45 min at 37°C, followed by o-
phenylenediamine dihydrochloride and H2O2 for 15 min
at 37°C. The reaction was stopped after 10 min with 0.5 M
H2SO4, and the absorbance at 492 nm were recorded. Cut
off absorbance for negative and positive IgM ELISA results
were 0.136 and 0.167, respectively.
Table 6 Diagnostic validity test of ELISA
True positive False positive True negative False negative
18 0 78 4
Sensitivity% Specificity% Positive predictive% Negative predictive % Efficacy%
81.8% 100% 100% 95.1% 97.7%
Table 7 Diagnostic validity test of PCR
True positive False positive True negative False negative
22 0 78 0
Sensitivity% Specificity% Positive predictive% Negative predictive % Efficacy%
100% 78% 100% 100% 99.7%
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Association between PCR and ELISA for diagnosis of
HBoV infection was evaluated using CHI square test. Sig-
nificance (p < 0.05). Diagnostic validity test including
sensitivity, specificity, positive and negative predictive
values were calculated considering the PCR a reference
method for diagnosis of HBoV infection. The diagnostic
power of both ELISA and PCR was estimated using the
efficacy rate.
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Table 8 Primer used for the amplification of HBoV
Primer Sequence (5’-3’) Amplicon size
(bp)
Purpose
HBoV188F GAGCTCTGTAAGTACTATTAC 354 Qualitative
PCR
HBoV542R CTCTGTGTTGACTGAATACAG 354 Qualitative
PCR
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